Formulary and Therapeutic Interchanges
3rd Quarter, 2023 (updated August 2, 2023)
| Class | Non-Preferred | Preferred Alternatives |
|---|---|---|
| ANTIDIABETICS | Basaglar, Toujeo Max, Toujeo Solo, Admelog Solo, Rybelsus | Insulin Glargine, Insulin Lisp, Insulin Lispro Kwik, Insulin Aspart, Insulin Aspart Kwik, Ozempic* |
| ADHD/ANTI-NARCOLEPSY/ANTI-BESITY/ANOREXIANTS | Focalin XR, Focalin, Adhansia Xr, Aptensio XR, Jornay PM, Quillivant, Amphet/dextr, Mydayis, Strattera, Intuniv |
Dexmethylphenidate, Dexmethylphenidate ER, Concerta, Methylin, Methylphenidate, Quillichew, Adderall, Adderall XR, Atomoxetine, Guanfacine, Qelbree |
| ANTIASTHMATIC AND BRONCHODILATOR AGENTS | Budes/formot, Proair Respi, Flutic/salme, Wixela Inhub, Fluticas HFA, Budesonide |
Symbicort, Ventolin HFA, Proventil HFA, Advair Diskus, Advair HFA, Spiriva, Flovent HFA, Pulmicort |
| ANTIDEPRESSANTS | Forfivo Xl, Trintellix, Desvenlafaxine, Viibryd |
Bupropion Hcl, Fluoxetine, Venlafaxine, Escitalopram |
| GASTROINTESTINAL AGENTS - MISC. | Delzicol, Canasa, Pentasa, Cimzia, Lubiprostone, Sevelamer |
Apriso, Lialda, Mesalamine, Amitiza, Renvela |
*This brand product has a generic equivalent recommended as an alternative.
*May require Prior Authorization
Abbreviations: ER = extended-release, XR = extended-release